{"transactions":[{"id":752497,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-03T20:30:13.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":96000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":96000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":96000},"source":{"system":"sec-edgar","filing":"0001493152-26-027100","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027100/ownership.xml","form_type":"4"}},{"id":866719,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-03T23:47:21.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":54876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date."}],"balance_after":54876,"derivative":{"exercise_price":0.98,"expiration_date":"2036-01-12","underlying":"Common Stock","underlying_shares":54876},"source":{"system":"sec-edgar","filing":"0001140361-26-007639","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126007639/form4.xml","form_type":"4"}},{"id":1087284,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2025-07-15T16:22:55.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":136900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":136900,"derivative":{"exercise_price":0.59,"expiration_date":"2035-07-11","underlying":"Common Stock","underlying_shares":136900},"source":{"system":"sec-edgar","filing":"0001641172-25-019725","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000164117225019725/ownership.xml","form_type":"4"}},{"id":1114854,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-06-11T22:00:33.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":22700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date."}],"balance_after":22700,"derivative":{"exercise_price":1.75,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":22700},"source":{"system":"sec-edgar","filing":"0001140361-25-022223","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125022223/form4.xml","form_type":"4"}},{"id":1235650,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true}}],"security":"Common Warrant","published_at":"2025-03-03T21:45:20.000Z","date":"2025-02-28","kind":"purchase","planned":false,"acquired":true,"shares":15061,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price for the Common Warrant is included in the purchase price for the shares of Common Stock reflected in Table I above."}],"balance_after":15061,"derivative":{"exercise_price":1.53,"exercise_date":"2025-02-28","expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":15061},"source":{"system":"sec-edgar","filing":"0001140361-25-006783","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125006783/form4.xml","form_type":"4"}},{"id":1235649,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-03-03T21:45:20.000Z","date":"2025-02-28","kind":"purchase","planned":false,"acquired":true,"shares":15061,"price":1.66,"value":25001.26,"ownership":{"direct":true},"balance_after":78851,"source":{"system":"sec-edgar","filing":"0001140361-25-006783","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125006783/form4.xml","form_type":"4"}},{"id":1451708,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2024-07-18T21:35:11.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":1627,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option disclosed on this Form 4 was not previously reported due to an administrative oversight."},{"field":"shares","element":"transactionShares","label":"F2","text":"Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests annually in three equal installments commencing on May 24, 2024."}],"balance_after":1627,"derivative":{"exercise_price":152.46,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":1627},"source":{"system":"sec-edgar","filing":"0001493152-24-028404","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315224028404/ownership.xml","form_type":"4"}},{"id":1469465,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-06-25T20:05:11.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date."}],"balance_after":9000,"derivative":{"exercise_price":2.86,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001140361-24-031293","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124031293/form4.xml","form_type":"4"}},{"id":1589476,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-07T17:45:21.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5714,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Company Common Stock subject to the Company Options vest on June 7, 2024."}],"balance_after":0,"derivative":{"exercise_price":13.72,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":5714},"source":{"system":"sec-edgar","filing":"0000950170-24-028188","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028188/ownership.xml","form_type":"4"}},{"id":1589475,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-07T17:45:21.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These Company Options are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":13.79,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000950170-24-028188","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028188/ownership.xml","form_type":"4"}},{"id":1589474,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-07T17:45:21.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a \"Company Option\") vest in thirty-six (36) equal monthly installments following May 19, 2023."}],"balance_after":0,"derivative":{"exercise_price":13.79,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-028188","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028188/ownership.xml","form_type":"4"}},{"id":1589473,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-03-07T17:45:21.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12142,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson (\"J&J\"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of March 7, 2024 (such date and time of such Merger, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each of these restricted stock units (\"RSUs\") represents a contingent right to receive one share of common stock of the Issuer (\"Company Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs vest as follows: on the earlier of (i) the one year anniversary of the grant date of June 7, 2023, and (ii) the day before the next annual general meeting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs vest as follows: on the earlier of (i) the one year anniversary of the grant date of June 7, 2023, and (ii) the day before the next annual general meeting."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12142},"source":{"system":"sec-edgar","filing":"0000950170-24-028188","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028188/ownership.xml","form_type":"4"}},{"id":1828604,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-07-17T21:26:34.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date."}],"balance_after":9000,"derivative":{"exercise_price":5.13,"expiration_date":"2033-07-14","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001140361-23-034831","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123034831/form4.xml","form_type":"4"}},{"id":1860829,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T16:17:34.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the options is equal to the fair market value per ordinary share on the grant date based on the trading price of the ADS."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vested on June 6, 2023."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares (\"ADSs\"). Each ADS represents seven (7) Ordinary Shares of the Issuer."}],"balance_after":17500,"derivative":{"exercise_price":1.97,"expiration_date":"2033-05-18","underlying":"Ordinary Shares","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000899243-23-015185","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000089924323015185/doc4.xml","form_type":"4"}},{"id":1860828,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T16:17:34.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the options is equal to the fair market value per ordinary share on the grant date based on the trading price of the ADS."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest on June 7, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares (\"ADSs\"). Each ADS represents seven (7) Ordinary Shares of the Issuer."}],"balance_after":40000,"derivative":{"exercise_price":1.96,"expiration_date":"2033-06-07","underlying":"Ordinary Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-23-015185","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000089924323015185/doc4.xml","form_type":"4"}},{"id":1860827,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-06-09T16:17:34.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares (\"ADSs\"). Each ADS represents seven (7) Ordinary Shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of Restricted Stock Units (the \"RSUs\") payable solely in Ordinary Shares of the Issuer that vest as follows: on the earlier of (i) the one year anniversary of the date of grant and (ii) the day before the next annual general meeting."}],"balance_after":85000,"source":{"system":"sec-edgar","filing":"0000899243-23-015185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000089924323015185/doc4.xml","form_type":"4"}},{"id":1876702,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-26T20:20:00.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the options is equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares (\"ADSs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Ordinary Shares subject to the option vest in thirty-six (36) equal monthly installments following May 19, 2023."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven (7) Ordinary Shares of the Issuer."}],"balance_after":210000,"derivative":{"exercise_price":1.97,"expiration_date":"2033-05-18","underlying":"Ordinary Shares","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0000899243-23-013994","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000089924323013994/doc4.xml","form_type":"4"}},{"id":2086305,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":1750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The Reporting Person paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The warrant is immediately exercisable in full."}],"balance_after":1750,"derivative":{"exercise_price":11.5,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086304,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":17903,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The warrant is immediately exercisable in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by Asclepius Life Sciences Fund, L.P (\"ALS Fund\"). Reporting Person serves as the managing member of ALS Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":17903,"derivative":{"exercise_price":11.58,"expiration_date":"2023-10-31","underlying":"Common Stock","underlying_shares":17903},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086303,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":3022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The warrant is immediately exercisable in full."}],"balance_after":3022,"derivative":{"exercise_price":11.58,"expiration_date":"2023-10-31","underlying":"Common Stock","underlying_shares":3022},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086302,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":70881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The warrant is immediately exercisable in full."}],"balance_after":70881,"derivative":{"exercise_price":6.9,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":70881},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086301,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":79417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option vests in 3 equal annual installments commencing on January 28, 2023."}],"balance_after":79417,"derivative":{"exercise_price":16.36,"expiration_date":"2032-02-03","underlying":"Common Stock","underlying_shares":79147},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086300,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":126138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option vests in 3 equal annual installments commencing on February 8, 2022."}],"balance_after":126138,"derivative":{"exercise_price":16.36,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":126138},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086299,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":264838,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020."}],"balance_after":264838,"derivative":{"exercise_price":11.58,"expiration_date":"2029-04-02","underlying":"Common Stock","underlying_shares":264838},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086298,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":168761,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"100% of the option is immediately exercisable. The option vested on October 28, 2016."}],"balance_after":168761,"derivative":{"exercise_price":5.03,"expiration_date":"2026-10-28","underlying":"Common Stock","underlying_shares":168761},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086297,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":138980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015."}],"balance_after":138980,"derivative":{"exercise_price":5.03,"expiration_date":"2024-04-11","underlying":"Common Stock","underlying_shares":138980},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086296,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":18,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The Reporting Person paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date."}],"balance_after":1750,"derivative":{"exercise_price":10,"exercise_date":"2022-12-12","underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086295,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":43847,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held of record by MedicaRx Inc. (\"MRx\"). Reporting Person serves as the managing director of MRx. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":43847,"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086294,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":49636,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held of record by Asclepius Master Fund, LTD. (\"AM Fund\"). Reporting Person serves as the managing director of AM Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":49636,"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086293,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":85442,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by Asclepius Life Sciences Fund, L.P (\"ALS Fund\"). Reporting Person serves as the managing member of ALS Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":85442,"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086292,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":448909,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."}],"balance_after":448909,"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2219339,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Steve C","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T20:16:07.000Z","date":"2022-06-28","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date."}],"balance_after":9000,"derivative":{"exercise_price":3.9,"expiration_date":"2032-06-28","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001140361-22-024470","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036122024470/form4.xml","form_type":"4"}},{"id":2663669,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Steve C","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T23:15:26.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option will vest in full and become fully exercisable on June 17, 2022."}],"balance_after":9000,"derivative":{"exercise_price":9.95,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001140361-21-021499","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036121021499/form4.xml","form_type":"4"}},{"id":2663668,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Steve C","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-06-17T23:15:26.000Z","date":"2021-06-15","kind":"purchase","acquired":true,"shares":5882,"price":8.5,"value":49997.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on June 17, 2021, and such shares of common stock are subject to a lock up agreement between the Reporting Person and Cantor Fitzgerald & Co., pursuant to which the shares cannot be sold for 90 days following June 15, 2021."}],"balance_after":63790,"source":{"system":"sec-edgar","filing":"0001140361-21-021499","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036121021499/form4.xml","form_type":"4"}},{"id":3099734,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Steve C","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-25T22:57:22.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 23, 2023."}],"balance_after":9000,"derivative":{"exercise_price":1.45,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001140361-20-014781","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036120014781/form4.xml","form_type":"4"}},{"id":3263129,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Steve C","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-02-19T21:30:22.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":38400,"price":1.3,"value":49920.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on February 14, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 19,508 shares of common stock previously issued to the Reporting Person.  The Reporting Person was a former stockholder of privately held PDS Biotechnology Corporation, a Delaware corporation (\"Private PDS\").   The Reporting Person received such shares of Issuer in exchange for the shares of common stock the Reporting Person formerly held in Private PDS in connection with the previously disclosed business combination with Private PDS, which was consummated on March 15, 2019."}],"balance_after":57908,"source":{"system":"sec-edgar","filing":"0001140361-20-003644","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036120003644/form4.xml","form_type":"4"}},{"id":3474676,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Steve C","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-01T20:50:37.000Z","date":"2019-06-28","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 28, 2022."}],"balance_after":9000,"derivative":{"exercise_price":5.99,"expiration_date":"2029-06-28","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001127602-19-023251","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760219023251/form4.xml","form_type":"4"}}]}